GoodRx Reveals Americans Overspent on Weight Loss Medications by $200 Million This Year, Fills Still Surged
05 Décembre 2024 - 3:00PM
Business Wire
In 2024, fills for Wegovy and Zepbound
increased by over 100% and 300%, respectively
GoodRx (Nasdaq: GDRX), the leading prescription savings platform
in the U.S., today released a new Weight Loss Medications Tracker
that provides an inside look at fill trends and spending patterns
for weight loss medications across the U.S. The company found that
limited insurance coverage and high out-of-pocket costs aren’t
slowing down interest in popular drugs used for weight loss such as
Mounjaro, Ozempic, Wegovy, and Zepbound. In fact, some of these
popular drugs have seen fills more than double in just the past
year. What’s more, GoodRx’s research shows that Americans overspent
by at least $200 million in 2024 by paying the full retail price
for their weight loss medications and not leveraging savings
available on GoodRx, showcasing an astounding willingness to access
these medications at any cost.
Highlights from the new research include:
- Surging fill rates: Even as patients grapple with high
costs and limited insurance coverage, demand for weight loss
medications is skyrocketing. Since the start of 2024, fills for
Wegovy and Zepbound increased by 100% and 300%, respectively.
- Limited insurance coverage: Despite growing interest and
proven health benefits, GIP and GLP-1 agonists are still not widely
covered by insurance when prescribed specifically for weight loss.
In fact, nearly 1 in 5 people with commercial insurance have no
coverage of GIP and GLP-1 agonists prescribed for weight loss at
all. For example, only 9% of people with commercial insurance have
unrestricted coverage of Zepbound and just 14% have unrestricted
coverage of Wegovy. Even with insurance coverage, out-of-pocket
costs are still high with the average person taking Zepbound paying
over $2,500 a year in insurance copays.
- Regional disparities: Some states see higher use of
weight loss medications than others. Surprisingly, Alaska leads the
nation with the highest overall fill rate for weight loss
medications. Massachusetts, New Jersey, Rhode Island, and Delaware
see higher rates for medications specifically targeting weight
loss, such as Wegovy, Zepbound, Saxenda, Qsymia, and
phentermine.
“GLP-1 and GIP medications have proven extremely effective in
helping reduce and manage weight in overweight individuals, yet
many health insurance plans lack necessary coverage and create cost
barriers for many people in need, ” says Tori Marsh, MPH, Director
of Research at GoodRx. “Our latest findings reveal that Americans
overspent by hundreds of millions on these essential treatments in
2024 alone. At GoodRx, we’re committed to bridging this gap by
offering significant savings, ensuring that more people can afford
their necessary medications.”
GoodRx Can Help You Save
Before spending money out of pocket, consumers should check
GoodRx to find ways to save on popular weight loss medications.
Patients can save an average of $250 per month, or $3,000 annually,
on commonly prescribed GLP-1 and GIP medications.
In addition to GLP-1’s, GoodRx recently announced a deal with
VIVUS for its oral weight-loss medication QSYMIA® to offer
consumers an exclusive low cash price at more than 70,000 retail
pharmacy locations nationwide.
Learn More From Trusted Doctors, Pharmacists & Health
Experts
Weight loss medications can be expensive and hard to understand.
To help support consumers on their weight loss journeys, GoodRx
offers credible, timely and actionable information to help people
learn more about the process, get information about common
concerns, uncover treatment options, and access significant
savings. Each article is researched and written by a team of
editorial experts, and clinical content is written and reviewed by
a team of medical experts that includes physicians, pharmacists,
and more.
To find savings and trusted health information, go to
www.goodrx.com/glp-1-discounts
About GoodRx
GoodRx is the leading prescription savings platform in the U.S.
Trusted by more than 25 million consumers and 750,000 healthcare
professionals annually, GoodRx provides access to savings and
affordability options for generic and brand-name medications at
more than 70,000 pharmacies nationwide, as well as comprehensive
healthcare research and information. Since 2011, GoodRx has helped
consumers save over $75 billion on the cost of their
prescriptions.
GoodRx periodically posts information that may be important to
investors on its investor relations website at
https://investors.goodrx.com. We intend to use our website as a
means of disclosing material nonpublic information and for
complying with our disclosure obligations under Regulation FD.
Accordingly, investors and potential investors are encouraged to
consult GoodRx’s website regularly for important information, in
addition to following GoodRx’s press releases, filings with the
Securities and Exchange Commission (the “SEC”) and public
conference calls and webcasts. The information contained on, or
that may be accessed through, GoodRx’s website is not incorporated
by reference into, and is not a part of, this press release.
GoodRx Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including, without limitation,
statements regarding anticipated consumer savings and
accessibility; and the objectives and potential benefits and value
of the GoodRx research and savings. These statements are neither
promises nor guarantees, but involve known and unknown risks,
uncertainties and other important factors that may cause GoodRx’s
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements, including,
but not limited to, risks relating to GoodRx’s ability to achieve
broad market education and change consumer purchasing habits,
changes in medication pricing and pricing structures, GoodRx’s
reliance on a limited number of industry participants, and the
important factors discussed in the section entitled “Risk Factors”
in GoodRx’s Annual Report on Form 10-K for the year ended December
31, 2023, and GoodRx’s other filings with the Securities and
Exchange Commission. Any such forward-looking statements are based
on current expectations, projections and estimates as of the date
of this press release. While GoodRx may elect to update such
forward-looking statements at some point in the future, GoodRx
disclaims any obligation to do so, even if subsequent events cause
GoodRx’s views to change.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241205403452/en/
Media Contact press@goodrx.com
GoodRx (NASDAQ:GDRX)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
GoodRx (NASDAQ:GDRX)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024